Enhancing drug bioavailability for Parkinson's disease: The promise of chitosan delivery mechanisms.

IF 1 Q4 PHARMACOLOGY & PHARMACY
Mohammad Arshad Javed Shaikh, Gaurav Gupta, Pawan Bagiyal, Saurabh Gupta, Santosh Kumar Singh, Ramkumar Pillappan, Dinesh Kumar Chellappan, Parteek Prasher, Vikas Jakhmola, Thakur Gurjeet Singh, Harish Dureja, Sachin Kumar Singh, Kamal Dua
{"title":"Enhancing drug bioavailability for Parkinson's disease: The promise of chitosan delivery mechanisms.","authors":"Mohammad Arshad Javed Shaikh, Gaurav Gupta, Pawan Bagiyal, Saurabh Gupta, Santosh Kumar Singh, Ramkumar Pillappan, Dinesh Kumar Chellappan, Parteek Prasher, Vikas Jakhmola, Thakur Gurjeet Singh, Harish Dureja, Sachin Kumar Singh, Kamal Dua","doi":"10.1016/j.pharma.2024.07.008","DOIUrl":null,"url":null,"abstract":"<p><p>Parkinson's disease (PD) is a widely seen neurodegenerative condition recognized by misfolded α-synuclein (αSyn) protein, a prominent indicator for PD and other synucleinopathies. Motor symptoms like stiffness, akinesia, rest tremor, and postural instability coexist with nonmotor symptoms that differ from person to person in the development of PD. These symptoms arise from a progressive loss of synapses and neurons, leading to a widespread degenerative process in multiple organs. Implementing medical and surgical interventions, such as deep brain stimulation, has enhanced individuals' overall well-being and long-term survival with PD. It should be mentioned that these treatments cannot stop the condition from getting worse. The complicated structure of the brain and the existence of a semi-permeable barrier, commonly known as the BBB, have traditionally made medication delivery for the treatment of PD a challenging endeavor. The drug's low lipophilic nature, enormous size, and peculiarity for various ATP-dependent transport mechanisms hinder its ability to enter brain cells. This article delves at the potential of drug delivery systems based on chitosan (CS) to treat PD.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales pharmaceutiques francaises","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.pharma.2024.07.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Parkinson's disease (PD) is a widely seen neurodegenerative condition recognized by misfolded α-synuclein (αSyn) protein, a prominent indicator for PD and other synucleinopathies. Motor symptoms like stiffness, akinesia, rest tremor, and postural instability coexist with nonmotor symptoms that differ from person to person in the development of PD. These symptoms arise from a progressive loss of synapses and neurons, leading to a widespread degenerative process in multiple organs. Implementing medical and surgical interventions, such as deep brain stimulation, has enhanced individuals' overall well-being and long-term survival with PD. It should be mentioned that these treatments cannot stop the condition from getting worse. The complicated structure of the brain and the existence of a semi-permeable barrier, commonly known as the BBB, have traditionally made medication delivery for the treatment of PD a challenging endeavor. The drug's low lipophilic nature, enormous size, and peculiarity for various ATP-dependent transport mechanisms hinder its ability to enter brain cells. This article delves at the potential of drug delivery systems based on chitosan (CS) to treat PD.

提高帕金森病药物的生物利用度:壳聚糖给药机制的前景。
帕金森病(PD)是一种广泛存在的神经退行性疾病,其特征是α-突触核蛋白(αSyn)蛋白折叠错误,这是帕金森病和其他突触核蛋白病的主要指标。在脊髓灰质炎的发病过程中,僵硬、运动障碍、静止性震颤和姿势不稳等运动症状与非运动症状并存,这些症状因人而异。这些症状源于突触和神经元的逐渐丧失,导致多个器官出现广泛的退行性病变。脑深部刺激等医疗和外科干预措施提高了帕金森病患者的整体健康水平和长期存活率。值得一提的是,这些治疗方法并不能阻止病情恶化。大脑结构复杂,存在半透膜屏障(俗称 "BBB"),这使得治疗帕金森氏症的药物输送一直是一项具有挑战性的工作。药物的低亲脂性、巨大的体积以及各种依赖 ATP 的转运机制的特殊性阻碍了其进入脑细胞的能力。本文深入探讨了基于壳聚糖(CS)的给药系统治疗帕金森病的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annales pharmaceutiques francaises
Annales pharmaceutiques francaises PHARMACOLOGY & PHARMACY-
CiteScore
1.70
自引率
7.70%
发文量
98
期刊介绍: This journal proposes a scientific information validated and indexed to be informed about the last research works in all the domains interesting the pharmacy. The original works, general reviews, the focusing, the brief notes, subjected by the best academics and the professionals, propose a synthetic approach of the last progress accomplished in the concerned sectors. The thematic Sessions and the – life of the Academy – resume the communications which, presented in front of the national Academy of pharmacy, are in the heart of the current events.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信